Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: an Open Label Extension

Stanford University

Summary

The goal of this study is to target the neurobiology of restricted and repetitive behaviors in children with autism spectrum disorder using N-acetylcysteine (NAC), a well-tolerated nutritional supplement that has shown promise for reducing symptom severity in recent small-scale trials. The findings from this research will shed light on the mechanisms of action underlying the clinical benefits of NAC and the effects of NAC on altering restricted and repetitive behavior symptom severity in children with autism spectrum disorder.

Eligibility

Age range: 3–13 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * participation in an associated single-dose (IRB-54931, NCT04278898) or randomized, controlled trial of NAC (IRB- 68353, NCT05664789). * stable medication regimens (≥ 30 days) with no anticipated changes during the trial. Exclusion criteria: • the presence of significant medical problems that reduce medical stability.

Interventions

Drug
N-acetylcysteine
12 week administration of N-Acetylcysteine to target restricted repetitive behavior severity.

Location

Stanford University School of Medicine
Stanford, California

Targeting the Neurobiology of Restricted and Repetitive Behaviors in Children With Autism Using N-acetylcysteine: an Open Label Extension

Summary

Eligibility

Interventions

Location

Run this study?

Details

Conditions